Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
COX-2 inhibitors, lithium interactions
Creatine kinase, psychotropic agent effects
creatinine clearance (CrCl), renal function assessment
Creatinine phosphokinase, antipsychotic medication monitoring
Cultural beliefs, influencing adherence
Cytisine clinical effectiveness for smoking cessation adverse effects
cytochrome (CYP) function antidepressant interactions with enzymes alcohol and substrates for enzymes caffeine metabolism/clearance genetics Psychotropic drugs and cytochrome (CYP) function enzyme phenotype frequency by ancestry nicotine/smoking effects
Cognitive decline, anticholinergic drugs
Combination treatment
combined oral contraceptive pill (COCP), premenstrual syndrome
Commonly used treatments, generally well supported by published literature (no preference implied by order)
Communication, patient factor in prescribing
Community detoxification, alcohol withdrawal
Community Treatment Order (CTO), Mental Health Act
Comorbid with eating disorders
Constipation causing drugs, avoid in hepatic impairment
Conventional sublingual buprenorphine daily treatment doses and recommended corresponding doses of weekly and monthly Buvidal
co-prescribed with warfarin leading to non-GI bleeding risk
Countertherapeutic use of medication
COVID-19
C-reactive protein in blood, psychotropic agent effects
creatine kinase (CK) elevations, antiretrovirals
Creatinine in blood, psychotropic agent effects
Cross-tapering, switching